On February 17, 2023, Boaz Pharmaceuticals Inc. ("Boaz" or the “Company") made an assignment into Bankruptcy pursuant to section 49(1) of the Bankruptcy and Insolvency Act, RSC 1985, c B-3 (the “BIA"). Deloitte Restructuring Inc. (“Deloitte") was appointed as Trustee of the Bankruptcy on the same date.
On September 5, 2024, The Trustee obtained its discharge.
If you have questions or require further information, please contact Naomi McGregor at 403-503-1423 or naomcgregor@deloitte.ca
Last updated Oct 30, 2025
